The earnings call highlighted significant growth in revenue and patient reach, driven by VYVGART's performance and pipeline expansion. However, there were challenges in China and increased operating expenses. Despite these challenges, the call conveyed a strong positive outlook for the company's growth and innovation.

Company Guidance -

Q3 2025

During the call, Argenx provided comprehensive guidance on its financial performance and strategic initiatives. The company reported a robust 97% year-over-year growth for VYVGART across all approved indications, with second-quarter operating income reaching $967 million, including $949 million from product net sales. VYVGART's global patient base expanded to 15,000, including 2,500 CIDP patients within a year of launch. The U.S. market alone contributed $802 million to net sales, reflecting an 18% quarter-over-quarter growth. Argenx also highlighted their pipeline progress, with three Phase III assets advancing and four new molecules in Phase I studies. The company's strong financial position is underscored by a $3.9 billion cash balance, supporting its long-term growth vision and investments in innovation. The guidance emphasized continued growth, driven by expanding patient reach and maintaining consistent net revenue per patient, despite increased gross to net adjustments.

Exceptional Growth of VYVGART

VYVGART achieved a remarkable year-over-year growth of 97% across all approved indications, with 15,000 patients globally being treated, including 2,500 CIDP patients just one year into the launch.

Strong Financial Performance

Second quarter 2025 financial results showed a total operating income of $967 million, including $949 million in product net sales. This represents a 19% growth in product net sales compared to the first quarter of 2025.

Expansion of Pipeline

Argenx advanced four new molecules into its pipeline and initiated multiple registrational trials in large market opportunities like Sjögren's, myositis, and TED.

Positive Real-World Patient Outcomes

Patients like Lynn, a biomedical engineer and marathon runner with CIDP, report significant improvements in quality of life after switching to VYVGART Hytrulo prefilled syringe.

Global Market Expansion

VYVGART's global market presence expanded, with non-U.S. markets now representing more than 15% of global product net sales, and fast starts in markets like Japan and Germany.

arGEN X (GB:0QW0) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:0QW0 Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	3.89 / -	1.28	―	―	―
Jul 31, 2025	2025 (Q2)	2.64 / 3.27	0.415	687.47% (+2.85)	―	―
May 08, 2025	2025 (Q1)	2.15 / 2.29	-0.965	337.10% (+3.25)	―	―
Feb 27, 2025	2024 (Q4)	1.65 / 11.32	-1.552	829.51% (+12.87)	―	―
Oct 31, 2024	2024 (Q3)	0.13 / 1.28	-1.183	208.20% (+2.46)	―	―
Jul 25, 2024	2024 (Q2)	-0.83 / 0.41	-1.538	126.98% (+1.95)	―	―
May 09, 2024	2024 (Q1)	-0.72 / -0.96	-0.473	-104.02% (-0.49)	―	―
Feb 29, 2024	2023 (Q4)	-1.19 / -1.55	-0.66	-135.15% (-0.89)	―	―
Oct 31, 2023	2023 (Q3)	-1.35 / -1.18	-4.261	72.24% (+3.08)	―	―
Jul 27, 2023	2023 (Q2)	-1.53 / -1.54	-3.752	59.01% (+2.21)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:0QW0 Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	€518.28	€593.70	+14.55%
May 08, 2025	€549.35	€488.35	-11.10%
Feb 27, 2025	€598.91	€609.95	+1.84%
Oct 31, 2024	€513.16	€529.63	+3.21%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does arGEN-X SE (GB:0QW0) report earnings?

arGEN-X SE (GB:0QW0) is schdueled to report earning on Oct 30, 2025, TBA (Confirmed).

What is arGEN-X SE (GB:0QW0) earnings time?

arGEN-X SE (GB:0QW0) earnings time is at Oct 30, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of arGEN-X SE stock?

The P/E ratio of arGEN X is N/A.

What is GB:0QW0 EPS forecast?

GB:0QW0 EPS forecast for the fiscal quarter 2025 (Q3) is 3.89.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing